Baseline characteristics of 106 patients with CLL
| Characteristic . | No. . |
|---|---|
| Sample size | 106 |
| Age, y | |
| Median | 61 |
| Range | 39-85 |
| Sex, % | |
| Female | 34 |
| Male | 66 |
| Rai stage, % | |
| Low, 0 | 36 |
| Intermediate, I-II | 56 |
| High, III-IV | 8 |
| Received prior therapy for CLL, % | |
| Yes | 20 |
| No | 80 |
| IgVH mutational status, n/N (%) | |
| Unmutated, ≥ 98% homology to germline | 57/106 (54) |
| Mutated, 98% homology to germline | 44/106 (41) |
| Not evaluable | 5/106 (5) |
| Prioritized interphase FISH, n/N (%) | |
| 17p deletion | 14/106 (13) |
| 11q deletion | 9/106 (9) |
| 12q trisomy | 15/106 (14) |
| Normal karyotype | 19/106 (18) |
| 13q deletion (sole abnormality) | 49/106 (46) |
| Multiple cytogenetic abnormalities | 22/106 (21) |
| Zap 70 expression, n/N (%) | |
| Negative, ≤ 20% | 50/106 (47) |
| Positive, 20% | 52/106 (49) |
| Not evaluable | 4/106 (4) |
| p53 mutation, n/N (%) | |
| Unmutated | 90/106 (85) |
| Mutated | 16/106 (15) |
| Characteristic . | No. . |
|---|---|
| Sample size | 106 |
| Age, y | |
| Median | 61 |
| Range | 39-85 |
| Sex, % | |
| Female | 34 |
| Male | 66 |
| Rai stage, % | |
| Low, 0 | 36 |
| Intermediate, I-II | 56 |
| High, III-IV | 8 |
| Received prior therapy for CLL, % | |
| Yes | 20 |
| No | 80 |
| IgVH mutational status, n/N (%) | |
| Unmutated, ≥ 98% homology to germline | 57/106 (54) |
| Mutated, 98% homology to germline | 44/106 (41) |
| Not evaluable | 5/106 (5) |
| Prioritized interphase FISH, n/N (%) | |
| 17p deletion | 14/106 (13) |
| 11q deletion | 9/106 (9) |
| 12q trisomy | 15/106 (14) |
| Normal karyotype | 19/106 (18) |
| 13q deletion (sole abnormality) | 49/106 (46) |
| Multiple cytogenetic abnormalities | 22/106 (21) |
| Zap 70 expression, n/N (%) | |
| Negative, ≤ 20% | 50/106 (47) |
| Positive, 20% | 52/106 (49) |
| Not evaluable | 4/106 (4) |
| p53 mutation, n/N (%) | |
| Unmutated | 90/106 (85) |
| Mutated | 16/106 (15) |